Can THC Cause Atrial Fibrillation (AFib)?

THC has a plausible biological mechanism for triggering atrial fibrillation, and some large observational studies have found a statistical link between cannabis use and AFib, but the evidence is surprisingly inconsistent. A major longitudinal study of over 150,000 people found no increased risk at all, while a separate meta-analysis pooling data from millions of participants found roughly 55 percent higher odds of atrial arrhythmias among cannabis users. That kind of disagreement usually points to confounding factors muddying the picture, and the THC-AFib question has a big one: tobacco.

What the Largest Studies Actually Found

The most direct evidence comes from a handful of large studies that tracked cannabis users over time or compared them against non-users in medical databases. Their conclusions pull in opposite directions. A longitudinal cohort study following over 150,000 participants for about six years found no statistically significant difference in new-onset AFib between cannabis users and never-users. Occasional users had essentially the same risk, and even frequent users showed no meaningful increase after adjusting for other factors.¹

A large retrospective multicenter analysis, on the other hand, found that cannabis users had about 55 percent higher rates of AFib or atrial flutter compared to non-users.² A meta-analysis pooling seventeen observational studies with more than 81 million total participants found a similar figure, with recreational cannabis use tied to roughly 55 percent higher odds of atrial arrhythmias. But the authors flagged extreme variability across studies, which is a sign that the individual study designs and the populations they examined differed enough to make the pooled number unreliable on its own.³

So the honest answer is that the epidemiological picture remains genuinely unsettled. When studies that say “no risk” and studies that say “about 50 percent more risk” coexist, neither can be dismissed outright, and neither should be quoted as the final word. What matters for a person trying to understand their own situation is why those studies disagree and what mechanisms could link THC to a heart rhythm disturbance even if the population-level statistics are messy.

How THC Can Disturb Heart Rhythm

Whether or not the big population studies agree, the biology gives THC a credible path to triggering arrhythmia. THC binds to CB1 receptors in the cardiovascular system, and that binding tilts the autonomic nervous system toward sympathetic activation. In practical terms, your body responds to THC the way it responds to a stress hormone surge: the heart speeds up, and levels of norepinephrine and epinephrine rise in the bloodstream.⁴ That increased sympathetic drive boosts the firing rate of the sinus node, the heart’s natural pacemaker, and shortens the electrical recovery window (the action potential duration) of heart muscle cells. When that recovery window gets shortened unevenly across different patches of atrial tissue, it creates the conditions for tiny electrical circuits to form and self-sustain, and that is the basic electrical signature of AFib.

There is also a dose-dependent twist. THC produces a biphasic response: lower doses tend to push heart rate up through sympathetic activation, while higher doses can swing the other way and cause bradycardia.⁴ Rapid swings in autonomic tone in either direction are a known arrhythmia trigger, so the risk isn’t purely about heart rate going up. It’s about the nervous system whipsawing the heart in ways it doesn’t expect.

The Tobacco Problem

One of the biggest reasons the population-level data is so contradictory probably comes down to a confounding factor that’s hard to fully separate from cannabis use: tobacco. Many cannabis users also smoke tobacco, and tobacco is a well-established independent risk factor for AFib. Studies that pull their cannabis-user cohorts from hospital records or insurance databases often can’t cleanly distinguish the cardiac effects of cannabis from the effects of co-occurring tobacco use.

A nationwide propensity-matched analysis tried to get around this by looking specifically at young men with cannabis use disorder who did not have concomitant tobacco use. After adjusting for confounders, the association between cannabis use disorder and AFib-related hospitalizations was not statistically significant, with odds that could easily have been due to chance.⁵ That finding doesn’t prove THC is harmless for heart rhythm, but it raises a serious question about how much of the signal in the bigger positive studies is really coming from cannabis versus the tobacco smoked alongside it.

This pattern shows up over and over in cannabis-cardiovascular research. The users who show the highest rates of cardiac events also tend to be the ones who smoke blunts (tobacco leaf wraps), mix cannabis with tobacco in joints, or have histories of heavy cigarette use. When tobacco gets removed from the equation, the statistical signal weakens or vanishes. That doesn’t make the mechanistic concerns irrelevant, because THC clearly does alter heart rate and autonomic balance, but it does suggest the real-world risk may be smaller than the scariest headline numbers imply for someone who uses cannabis without tobacco.

Case Reports in Young, Otherwise Healthy People

Even if the population data is murky, case reports have documented individual episodes of AFib apparently triggered by cannabis use. One well-described case involved a 38-year-old woman with no significant medical history who arrived at an emergency department with palpitations and shortness of breath after smoking marijuana. She was found to be in AFib, and workup during her hospitalization turned up no cardiac or metabolic conditions that would have predisposed her to the arrhythmia. The AFib resolved on its own within three hours.⁶

Cases like this matter because they highlight the population most likely to be caught off guard: young adults with no structural heart disease and no prior history of arrhythmia. In an older person with hypertension, obesity, or sleep apnea, AFib has an obvious explanation. In a 30-something with a clean bill of health, cannabis is sometimes the only plausible trigger. The authors of that case report and several reviews have suggested that cannabis use should be considered as a possible cause of new-onset AFib, particularly in relatively young patients without other predisposing risk factors.⁶ The risk appears to be higher in younger users and in males, according to a comprehensive review of the epidemiological literature.⁷

The pattern in case reports is usually an acute event: someone uses cannabis, develops palpitations within minutes to a couple of hours, and the arrhythmia converts back to normal rhythm relatively quickly. That’s consistent with the pharmacological timeline of inhaled THC hitting the bloodstream, provoking a sympathetic surge, and then wearing off. It doesn’t look like the chronic, progressive AFib that develops over years in someone with an enlarged left atrium.

Dose, Frequency, and Tolerance

The heart rate increase from THC is not a fixed number. In a randomized crossover study of healthy adults, both a pure THC oil and a CBD-plus-THC combination significantly raised heart rate, but how much the heart rate jumped depended heavily on the person’s history with cannabis.⁸ A separate study comparing light and heavy users found that heavy male users had a substantially blunted heart rate response to THC. At one dose level, light male users’ hearts sped up by an average of about 36 beats per minute above baseline, while heavy male users’ hearts sped up by only about 19 beats per minute.⁹

This tolerance effect has real implications for arrhythmia risk. If the primary mechanism connecting THC to AFib is an acute sympathetic surge driving the heart rate up, then chronic heavy users may face a smaller trigger each time they use cannabis compared to someone using it for the first time or only occasionally. That could partly explain why the longitudinal study cited earlier, which tracked both occasional and frequent users, found no elevated AFib risk in either group. Frequent users may have developed enough cardiovascular tolerance that the acute jolt no longer reaches the threshold for triggering arrhythmia.

On the other hand, a first-time or very infrequent user who inhales a high-potency product could experience a much larger heart rate swing, potentially one large enough to push vulnerable atrial tissue into fibrillation. Today’s cannabis products, particularly concentrates and high-THC flower strains, deliver substantially more THC per use than products available a generation ago. A naive user taking a large dose from a vape pen or concentrate rig gets a bigger acute sympathetic hit than someone who smoked low-potency cannabis in the 1970s, and most of the older safety data was generated under those milder conditions.

CBD as a Possible Buffer

There is growing interest in whether cannabidiol (CBD) can blunt THC’s cardiovascular effects. The randomized crossover study mentioned above directly compared pure THC oil to a CBD-plus-THC combination and found that the combination produced a more attenuated pattern of cardiovascular responses than THC alone. THC by itself generated more pronounced changes in heart rate and hemodynamics, while adding CBD appeared to take the edge off.⁸

This is one study in healthy adults, so it would be premature to conclude that CBD “protects” against THC-induced AFib. But it fits with the broader pharmacological picture. CBD interacts with multiple receptor systems in ways that tend to oppose some of THC’s effects, including its sympathetic-activating properties. If a person is choosing cannabis products and is concerned about cardiac risk, a product with a meaningful ratio of CBD to THC may deliver a smaller cardiovascular hit than a pure-THC product, though how much smaller and whether that difference matters clinically for arrhythmia remains an open question.

Interestingly, the body’s own endocannabinoid system seems to play a largely protective role in cardiac health. Research in animal models has shown that higher endocannabinoid levels are associated with less tissue damage and fewer arrhythmias during heart attacks, and stimulating CB2 receptors (a different receptor from the CB1 receptor THC primarily activates) may even slow the progression of arterial plaque.¹⁰ The paradox is that the endocannabinoid system evolved partly to protect the heart, but flooding it with external THC, which hits CB1 receptors much harder than the body’s own endocannabinoids do, can tip the balance from protection toward disruption.

Synthetic Cannabinoids Are a Different and Worse Story

People sometimes lump natural cannabis and synthetic cannabinoids (products sold under names like Spice or K2) into the same category, but the cardiac risks are not comparable. Synthetic cannabinoids bind to CB1 receptors with far greater potency and often with full agonist activity, meaning they switch the receptor all the way on rather than partially activating it the way THC does. Laboratory work has shown that at least one synthetic cannabinoid, 5F-AKB48, directly blocks the hERG potassium channel, which is critical for the normal electrical reset of heart cells. Blocking that channel is the exact mechanism behind several prescription drugs that have been pulled from the market for causing fatal arrhythmias.¹¹

THC from natural cannabis does not appear to block the hERG channel in the same way. So while the arrhythmia conversation around natural cannabis is about sympathetic surges and indirect electrical effects, synthetic cannabinoids add a direct channel-blocking toxicity on top of all that. Emergency departments have documented far more dramatic cardiac events with synthetic cannabinoids, including ventricular tachycardia and cardiac arrest in otherwise healthy young people. If you’re evaluating your own risk and you see reassuring headlines about cannabis and heart rhythm, make sure the reassurance applies to the type of product you’re actually using. Synthetic cannabinoids are in a completely different risk class.

What to Watch For

If you use cannabis and are concerned about AFib, the practical picture looks roughly like this. The strongest warning signals are being a first-time or infrequent user, using a high-potency THC product, combining cannabis with tobacco or stimulants, and having a personal or family history of arrhythmia or structural heart disease. The risk profile shifts substantially based on context: a longtime daily user consuming moderate amounts of flower with a reasonable CBD content is in a very different situation from someone who hits a 90-percent-THC concentrate for the first time.

Symptoms that should prompt medical attention include a racing or pounding heartbeat that feels irregular (not just fast), lasting more than a few minutes after cannabis use; feeling lightheaded or faint during the episode; and chest pressure or shortness of breath that doesn’t resolve as the high fades. AFib episodes triggered by cannabis seem to be self-limiting in many documented cases, often resolving within hours without intervention, but that doesn’t mean they’re safe to ignore. Even a brief AFib episode can carry a stroke risk, and recurrent episodes can lead to progressive remodeling of the heart’s atrial tissue.

Anyone who has experienced an episode of AFib after cannabis use should tell their cardiologist or electrophysiologist about the timeline, including how soon after use symptoms began and how long they lasted. Case reports and clinical reviews indicate that cannabis is still frequently overlooked as a potential trigger in emergency settings, particularly in younger patients who don’t fit the classic AFib demographic of older adults with hypertension or valve disease.⁶ If you’ve had a documented episode and you’re deciding whether to continue using cannabis, that’s a conversation worth having with a doctor who knows both your cardiac history and the specifics of what you use.